glp-1 tirzepatide is use tripled among non-diabetics, reaching $5.8B in 2022 Frontiers Tirzepatide | GLP1 | Medical

How the buzz began GLP-1 drugs came onto the market for treating diabetes

As aforementioned, we observed accelerated roGFP2 re-oxidation in the WT, but not in dsbA , when adding monothiols to the cells and the opposite effect for GSSG, compensating the lack of DsbA, raising the question whether DsbB is somehow regulated by glutathione

31 Liraglutide subjects lost 4.8 kg in the group receiving 1.2 mg and 5.5 kg in the 1.8 mg group when compared to baseline

Beijers AJM, Jongen JLM, Vreugdenhil G

This creates a challenging bottleneck for formulators who need to deliver a functional dose to achieve the desired output